RBL LLC welcomes James Watson to board of directors
Txylo.com/10312852

Trending...
HOUSTON, June 17, 2025 ~ Houston, TX - RBL LLC, a biotech venture creation studio focused on developing groundbreaking medical technologies from Rice University, has announced the addition of James Watson to its board of directors. Watson, an operating partner at Andreessen Horowitz and a seasoned executive in the life sciences industry, brings a wealth of experience in business strategy, corporate development, and venture-backed company building to RBL LLC.

According to Paul Wotton, managing partner at RBL LLC, the appointment of James Watson is a strong endorsement of the company's model and potential. With his extensive background in all stages of biotech innovation, from company formation to valuable partnerships, Watson's insights into market dynamics and ability to drive successful outcomes will be crucial as RBL continues to grow.

Rice professor of bioengineering and managing partner of RBL LLC, Omid Veiseh also expressed his excitement about Watson joining the board. He believes that Watson's ability to bridge science and business, along with his track record in corporate development, aligns perfectly with RBL's mission to translate Rice University's biomedical breakthroughs into high-impact startups.

More on Txylo.com
In response to his appointment, James Watson stated that he was drawn to RBL's innovative approach to company creation and its positive impact on the Houston life sciences community. He praised the studio for its efficient approach in identifying promising technologies with clear clinical applications and establishing focused enterprises to advance them. He also highlighted the strategic positioning of RBL in Houston as a key factor in building successful scientific ventures.

Currently serving as an operating partner on the Bio + Health team at Andreessen Horowitz, Watson leads business and corporate development for the firm's life sciences portfolio. Prior to this role, he held executive positions at several biotech companies including Carmot Therapeutics and Sigilon Therapeutics. At Carmot Therapeutics, he led the raising of over $200 million for the company's pipeline and discovery platform and built business development relationships that contributed to its $2.7 billion acquisition by Roche. He also served as chief business officer and president ICT at Sigilon Therapeutics, where he led a $485 million cell therapies partnership with Lilly.

With an MBA from Indiana University and a bachelor's degree in economics from the University of Portsmouth, Watson brings a strong educational background to the RBL board.

Watson will join existing board members Wotton, Veiseh, Rima Chakrabarti, John Jaggers, Devyn Smith, and Paul Cherukuri. This accomplished group of leaders with deep expertise in biotech innovation, clinical translation, and venture building will provide strategic guidance to help drive RBL's continued growth and success.
Filed Under: Business
Show All News | Report Violation

0 Comments

Latest on Txylo.com